TB/HIV Drug Interactions

Updated Guidelines for the Use of Rifamycins for the Treatment of Tuberculosis Among HIV-Infected Patients Taking Protease Inhibitors or Nonnucleoside Reverse Transcriptase Inhibitors

Updated January 20, 2004

Table of Contents

Introduction

Mechanisms of rifamycin-antiretroviral drug interactions

Rifampin and antiretroviral therapy

Rifabutin and antiretroviral therapy

Other drug-interaction issues

Acquired rifamycin resistance

References

Table 1 - Recommendations for coadministering protease inhibitors and non-nucleoside reverse transcriptase inhibitors with rifampin

Table 2 - Recommendations for coadministering protease inhibitors and non-nucleoside reverse transcriptase inhibitors with rifabutin

Back to Top of Page

You will need Adobe Acrobat™ Reader v3.0 or higher to read pages that are in PDF format.  Download the Adobe Acrobat™ Reader.

If you have difficulty accessing any material on the DTBE Web site because of a disability, please contact us in writing or via telephone and we will work with you to make the information available.

Division of Tuberculosis Elimination
Attn: Content Manager, DTBE Web site
Centers for Disease Control and Prevention
1600 Clifton Rd., NE Mailstop E-10
Atlanta, GA 30333
(404) 639-8135
E-mail: tbinfo@cdc.gov

Home | What's New | Search | Site Map | Subscribe | Contact Us
Accessibility | Privacy Policy Notice | FOIA
CDC Home | Search | Health Topics A-Z

Centers for Disease Control & Prevention
National Center for HIV, STD, and TB Prevention
Division of Tuberculosis Elimination
Please send comments/suggestions/requests to: tbinfo@cdc.gov